Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Third Quarter results
View:
Post by BottomBroker on Nov 12, 2021 3:06pm

Third Quarter results

https://finance.yahoo.com/news/promis-neurosciences-announces-third-quarter-120000225.html
Comment by DavidKingCanada on Nov 12, 2021 3:57pm
Once again, ZERO news on any sort if Serology Test or Covid Test.  Zero Revenue from BCNI
Comment by Speyeder999 on Nov 13, 2021 11:09am
David, that isn't entirely correct. Because you brought it up, did a check on sedar and neatly tucked away in their interim financial statements  you will find that they expensed $98,K to the Immusafe effort (see below)......but that's as close to any news you'll get......AND  they chose to ignore any mention of any progress on the subject (ie: approvals, timelines ...more  
Comment by retiredcop on Nov 13, 2021 12:59pm
The Company is responsible to fund operating expenses, with prior notification of the planned expenditures, to bring the assay through regulatory approval. This is the delay that is holding back everthing we expect to see or hear. 
Comment by DavidKingCanada on Nov 13, 2021 2:56pm
Speyeder, thanks for that! 
Comment by Gbathat on Nov 12, 2021 11:22pm
We are on track to complete all IND enabling work in H2 2022 From Charles river... The purpose of IND-enabling studies is to secure approval to conduct the first-in-human clinical trials with a new drug. An IND application contains information on pharmacology and toxicology, manufacturing (e.g., composition, production, stability, etc.), human clinical study protocols, and investigator ...more  
ProMIS Neurosciences Inc